Clinical and Pharmacotherapeutic Relevance of the Double-Chain Domain of the Angiotensin II Type 1 Receptor Blocker Olmesartan

REFERENCES

• De Gasparo M, Catt J, Inagami T, Wright JW, Unger T. International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000:52; 415–472.
   PubMed Web of Science ®Google Scholar
• Miura S, Fujino M, Saku K. Angiotensin II receptor blocker as an inverse agonist: A current perspective. Curr Hypertens Rev 2005:1; 115–121.
   Google Scholar
• Costa T, Herz A. Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci USA 1989:86; 7321–7325.
   PubMed Web of Science ®Google Scholar
• Zou Y, Akazawa H, Qin Y, Sano M, Takano H, Minamino T, Makita N, Iwanaga K, Zhu W, Kudoh S, Toko H, Tamura K, Kihara M, Nagai T, Fukamizu A, Umemura S, Iiri T, Fujita T, Komuro I. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol 2004:6; 499–506.
   PubMed Web of Science ®Google Scholar
• Miura S, Saku K, Karnik SS. Molecular analysis of the structure and function of the angiotensin II type 1 receptor. Hypertens Res 2003:26; 937–943.
   PubMed Web of Science ®Google Scholar
• Miura S, Fujino M, Hanzawa H, Kiya Y, Imaizumi S, Matsuo Y, Tomita S, Uehara Y, Karnik SS, Yanagisawa H, Koike H, Komuro I, Saku K. Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J Biol Chem. 2006:281; 19288–19295.
   PubMed Web of Science ®Google Scholar
• Peralta CA, Kurella M, Lo JC, Chertow GM. The metabolic syndrome and chronic kidney disease. Curr Opin Nephrol Hypertens 2006:15; 361–365.
   PubMed Web of Science ®Google Scholar
• Segura J, Campo C, Gil P, Roldán C, Vigil L, Rodicio JL, Ruilope LM. Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol 2004:15; 1616–1622.
   PubMed Web of Science ®Google Scholar
• De Leeuw PW, Thijs L, Birkenhager WH, Voyaki SM, Efstratopoulos AD, Fagard RH, Leonetti G, Nachev C, Petrie JC, Rodicio JL, Rosenfeld JJ, Sarti C, Staessen JA; Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial. J Am Soc Nephrol 2002:13; 2213–2222.
   PubMed Web of Science ®Google Scholar
• Ohishi M, Takagi T, Ito N, Tatara Y, Hayashi N, Shiota A, Iwamoto Y, Katsuya T, Rakugi H, Ogihara T. Renal protective effect in hypertensive patients: the high doses of angiotensin II receptor blocker (HARB) study. Hypertens Res 2007:12; 1187–1192.
   Google Scholar
• Kiya Y, Miura SI, Imaizumi S, Uehara Y, Matsuo Y, Abe S, Jimi S, Urata H, Rye KA, Saku K. Reconstituted high-density lipoprotein attenuates postinfarction left ventricular remodeling in rats. Atherosclerosis 2009:203; 137–144.
   Google Scholar
• Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect. Circulation 2002:103; 672–678.
   Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001:345; 861–869.
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Delles C. Additional antiproteinuric effect of ultrahigh dose candesartan: A double-blind, randomized, prospective study. J Am Soc Nephrol 2005:16; 3038–3045.
   PubMed Web of Science ®Google Scholar
• Ohtake T, Oka M, Maesato K, Mano T, Ikee R, Moriya H, Kobayashi S. Pathological regression by angiotensin II type 1 receptor blockade in patients with mesangial proliferative glomerulonephritis. Hypertens Res 2008:3; 387–394.
   Google Scholar
• Varagic J, Frohlich ED, Susic D, Ahn J, Matavelli L, López B, Díez J. AT1 receptor antagonism attenuates target organ effects of salt excess in SHRs without affecting pressure. Am J Physiol Heart Circ Physiol 2008:294; 853–858.
   PubMed Web of Science ®Google Scholar
• Katayama S, Yagi S, Yamamoto H, Yamaguchi M, Izumida T, Noguchi Y, Inaba M, Inukai K. Is renoprotection by angiotensin receptor blocker dependent on blood pressure? The Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) Study. Hypertens Res 2007:30; 529–533.
   PubMed Web of Science ®Google Scholar
• Fliser D, Wagner KK, Loos A, Tsikas D, Haller H. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol 2005:16; 1135–1140.
   PubMed Web of Science ®Google Scholar
• Abadir PM, Carey RM, Siragy HM. Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice. Hypertension 2003:42; 600–604.
   PubMed Web of Science ®Google Scholar
• Dostal DE, Baker KM. The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ Res 1999:85; 643–650.
   PubMed Web of Science ®Google Scholar
• Sadoshima J, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993:75; 977–984.
   PubMed Web of Science ®Google Scholar
• McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, Tsuyuki RT, White M, Rouleau J, Latini R, Maggioni A, Young J, Pogue J. Comparison of candesartan, enalapril and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study: The RESOLVD pilot study investigators. Circulation 1999:100; 1056–1064.
   PubMed Web of Science ®Google Scholar
• Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs 2005:5; 41–50.
   PubMedGoogle Scholar
• Brunner HR, Arakawa K. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals. Clin Drug Investig 2006:26; 185–193.
   PubMed Web of Science ®Google Scholar